435 results
Primary Objectives: To evaluate the overall bowel cleansing efficacy and the *Excellent plus Good* cleansing rate in the colon ascendens of a 1-day day before-only split-dosing regimen with NER1006 compared to a 1-day day before-only split-dosing…
Primary Objectives:- To evaluate and compare the overall survival (OS) of subjects with advanced or metastatic adenocarcinoma of the pancreas when treated with JAK 1/2 Inhibitor in combination with capecitabine versus capecitabine alone.Secondary…
Primary Study Objective: To evaluate the effect of telotristat etiprate versus placebo over the double-blind portion of the study on the incidence of treatment-emergent adverse events (TEAEs)
The aim of this study is to compare the additional diagnostic yield (adenoma detection rate) of G-EYE colonoscopy with that of standard high definition colonoscopy.
The objective of this study is to compare the efficacy of Infliximab-biosimilar to Infliximab-innovator and to demonstrate its noninferiority up to 30 weeks, in patients with ulcerative colitis or Crohn*s disease in remission under treatment with…
Primary objective: To evaluate the effects of eHealth therapy and usual care in IBD patients with arthralgia and to compare the effects of eHealth interventions plus usual care with just usual care in IBD patients with arthralgia.
The primary objective of the study is to gain insight in the short term and long term effects of the EFCT-ODA therapy on 1) dyadic coping abilities in the relationship and 2) relational satisfaction. Moreover, the process aspects of the ODA will be…
Primary:• To prove the superiority of a 12-week add-on treatment with 3.2 g/daygastro-resistant phosphatidylcholine granules (LT-02) in at least one of twodifferent dosing regimens versus LT-02 placebo for the induction ofremission in patients with…
The primary objective of this study is to compare PFS of ramucirumab in combination with capecitabine (or 5-fluorouracil [5-FU]) and cisplatin versus placebo in combination with capecitabine (or 5-FU) and cisplatin as first-line treatment in…
Primary Objective: In the CORAL study we want to determine whether increasing the inoculation dose of diarrhoeagenic E. coli to 5*10^10 CFU and addition of a second challenge 1*10^10 CFU will result in an increased effect-size and duration of…
To determine the efficacy and safety of MEDI4736 evaluated as a single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on 5-FU-containing or gemcitabine-…
Objective 1: To investigate the difference in prescribing proton pump inhibitors continuously rather than on demand in patient reported reflux symptoms, quality of life and self-rated health. Objective 2: To investigate whether the use of electronic…
To compare the efficacy of P-SNN to EUS-CGN with regard to decreasing chronic malignant pain in patients with inoperable intra-abdominal malignancies.
Primary:* To assess the efficacy of 2 x 1 mg/d budesonide effervescent tablets vs. placebo for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis (EoE).Secondary:* To study safety and tolerability…
To prolong the dysphagia-free period and to reduce the number of endoscopic dilations for patients with newly diagnosed, untreated benign anastomotic strictures after esophagectomy.
The aim of this study is to investigate the effects of early start versus delayed start of oral intake on postoperative recovery and pulmonary complications following esophagectomy. This is a non-inferiority trial.
The objective of this Phase III study is to evaluate the efficacy and safety of nintedanib in patients with mCRC after failure of previous treatment with standard chemotherapy and biological agents.
Primary:* To prove the superiority of a 48-weeks treatment with 3.2 g/day delayedreleasephosphatidylcholine (LT-02) versus placebo for the maintenance ofremission in patients with ulcerative colitis (UC)Secondary:* To study safety and tolerability…
The aim of this study is the efficacy of a simplified triple regimen at an energy setting of 12 J/cm2 instead of 2x2x15 J/cm2, without a cleaning phase in between, and its effect on the rate of stenosis and overall complications when using the Barrx…
Primary:* To determine the effect of vedolizumab IV compared to adalimumab SC on clinical remission at Week 52.Secondary:* To evaluate the effect of vedolizumab IV compared to adalimumab SC on mucosal healing at Week 52.* To evaluate the effect of…